A groundbreaking vector that can efficiently introduce multiple types of antigen proteins into recipients.
"BC-PIV" is a vector technology that presents large protein antigens while maintaining their three-dimensional structure, effectively inducing vaccine efficacy. It is an inactivated virus vaccine that achieves effective vaccine effects without the need for adjuvants. Additionally, we are also developing vaccines for infectious diseases such as Ebola virus, RSV, malaria parasites, and Zika virus. [Features] - Maintains three-dimensional structure - Capable of presenting large protein antigens - Efficiently induces vaccine efficacy - No adjuvant required *For more details, please refer to the catalog or feel free to contact us.
Inquire About This Product
basic information
【Merits】 ■ Capable of introducing multiple and high molecular weight foreign antigens ■ Multiple administration routes (nasal, intradermal, subcutaneous, intramuscular) ■ High antibody levels ■ CTL induction capability ■ Can address infectious diseases without vaccines *For more details, please refer to the catalog or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the catalog or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Biocomo Co., Ltd. is a drug discovery venture company that is working on the research and development of a new vaccine in collaboration with Professor Tetsuya Nosaka from the Graduate School of Medicine at Mie University, specializing in Infectious Disease Control Medicine and Molecular Genetics. Biocomo has successfully developed a new vaccine vector with different characteristics from existing vaccines in collaboration with the Nosaka laboratory. The aim is to create a vaccine that retains the high immune-inducing ability of live vaccines while eliminating the risk of infectious disease associated with live vaccines, and that can efficiently introduce large-sized protein/peptide antigens, which has been difficult with conventional vaccine technologies. To achieve these two characteristics, we are focusing on hPIV2 and engaging in research and development.